EOS: a Focussed Oncology Company Overview Forum della Ricerca e dell Innovazione Padova, May 16, 2008

Transcription

1 Growing and Nurturing Right Ideas EOS: a Focussed Oncology Company Overview Forum della Ricerca e dell Innovazione Padova, May 16, 2008 EOS S.p.A. (Ethical Oncology Science) Via Monte di Pietà 1/A, Milan, Italy;

2 Assets & Vision Ideally Suited to Venture Equity Innovative pipeline of targeted Oncology programs E-3810 multi kinase inhibitor with ideal selectivity profile IND Candidate HDACi unique approach in a field crowded by me-too Favourites Optimization Wnt Pathway Inhibitor: first in class in hot area Lead Development Clinical development alliance with Cephalon E/CEP first oral proteasome inhibitor in Phase I Serial entrepreneurs team with outstanding track record Financial support: Sofinnova Partners A key player in M&A and Partnering arena in 2 to 4 years 2

3 Focus on Areas of Sustained Growth The future of cancer treatment is in targeted therapeutics Their market value is expected to double by 2012 It will represent over 2/3 of the oncology market by then Values for are reported sales. Values for are forecast sales. Source: Evaluate Pharma. 3

4 Focus on Areas of Sustained Growth The future of cancer treatment is in targeted therapeutics 2007 global sales of small molecule kinase inhibitors were close to 6 billion $ while recombinant antibodies against growth factor receptors generated revenues over 7 billion $ Values for are reported sales. Values for are based on forecast sales. Source: Evaluate Pharma. 4

5 Attractive Exit Opportunities The strive to innovation will fuel value creation Biotech and Pharma portfolios are still crowded with me-too drugs with unimpressive differential, but focus is shifting Groundbreaking oncology projects will continue to offer hot exit opportunities to investors through M&A or partnering In 2007, 25% of all partnering deals were in cancer 5

6 An Innovative Pipeline The heterogeneity of cells within tumors as well as the redundancy of proliferative and survival pathways favor the developmentof drugs that affect multiple pathways Novel Anti-proliferative Mechanisms Multi-targeted compounds that act synergistically are expected to lead to superior efficacy with lower potential for dose limiting toxicities Multi Kinase Inhibitors The simultaneous inhibition of several cellular targets by poly-pharmacological intervention might have even greater potential in preventing the emergence of drug resistance in human malignancies Protein Homeostasis Control Modulating Gene Expression 6 BroxtemanH.J.et al., Drug Resist. Update 8:183, 2005; Budillon A. et al., Curr. DrugTargets 6:241, 2005; Daub H. et al., Nat Rev Drug Disc , 2004; Minucci S. et al., Nat. Rev. Cancer, 6:38, 2006

7 An Innovative Pipeline E-3810 multi kinase inhibitor IND Candidate Must-have in the portfolio of any Oncology market player Best in class potential for selectivity profile and activity WW (ex-china) rights Wnt Pathway Inhibitors Novel anti-proliferative agents with first in class potential Acquisition; WW rights retained E/CEP first oral proteasome inhibitor in clinical trials Clinical cooperation with Cephalon HDACi: structural breakthrough in a field crowded by me-too Drug-like molecules with high potency, high selectivity and best in class attributes WW rights; co-development with KarusTherapeutics; majority of economics retained 7

8 Pipeline Development: Outlook E/CEP Phase I Phase IIb RDP E-3810 Preclinical IND Phase I Phase IIa PoC HDACi Pharmaco/Tox CC Preclinical IND Phase I/IIa PoC Wnt Inhibitors Lead Opt. Pharmaco/Tox CC Preclinical IND E Lead Opt. 8 CC: Clinical Candidate; IND: Investigational New Drug or EU equivalent PoC: Clinical Proof of Concept; RDP: Registration Decision Point (i.e. roll-out to pivotal trial)

9 Pipeline Development: Outlook E/CEP Phase I Phase IIb RDP E-3810 Preclinical IND Phase I Phase IIa PoC HDACi Pharmaco/Tox CC Preclinical IND Phase I/IIa PoC Wnt Inhibitors Lead Opt. Pharmaco/Tox CC Preclinical IND E Lead Opt. Stage 1: From Preclinical to Clinical Stage 2: Focus on POC 9

10 Turning the Vision into a Plan Translational Medicine: the brain-power to turn the potential of innovation into real clinical progress, i.e. Selecting the right molecules Use more predictive preclinical models based on biomarkers Designing and implementing the right clinical plan Evolve from the one-fit-all, response-based paradigm (like with cytotoxics) to an early precise definition of potential responders based on early predictors of clinical benefit EOS has a nimble, cost-efficient and scalable infrastructure ideally suited for venture equity: Core expertise and project management are retained internally Resource-intensive activities are outsourced to a closely integrated and flexible network of selected partners 10

11 EOS Development Resources Process/Stage EOS Core Resources & Strategic Partners Outreach Medicinal Chemistry Scale up Synthesis CMC GMP Production Non-clinical Pharmacology GLP-Studies IND Package Biomarkers development Human and animal ADME Phase I &II Clinical Studies EOS Team at CISI, University of Milan EOS Team at Shanghai Chem Partner EOS CMC and QA Expert Nerviano Medical Sciences Accelera EOS Team at Mario Negri Institute (Milan) EOS Clinical Project Management Coop. with SENDO Several outsourced campaigns Cerep, Ambit, Oncotest Theradex 11

12 A Strong Management Team Jacques Theurillat, Chairman of the Board and Founder Former Deputy CEO and CFO for Serono with 20 years experience in operational, financial and strategic roles in the biotech industry Silvano Spinelli, CEO and Founder Co-Founder and CEO of Novuspharma, proven leader, with 20+ years experience in translating basic science into clinical testing with solid therapeutic product orientation; fund raising, IPO and M&A experience Gabriella Camboni, VP Development and Founder MD, Clinical Pharmacologist, with 18 years of experience in oncology drug development at Sandoz and Boehringer Mannheim, Co-Founder of Novuspharma, and lately European Head of Medical Affairs for Novartis Oncology Ennio Cavalletti, VP Operations and Founder DVM, toxicologist by training, with 20+ years experience in preclinical development of anticancer drugs. Co-Founder of Novuspharma, has extensive operational experience in outsourcing and QA 12

13 Merits of EOS Investment Opportunity Solid Investment Proposition Sound Science Scientific Program is synchronized with the business program Value inflection point is deliverable according to plan (timeline) and on budget Experienced Management Team Development Experience Fund Raising Experience Execution Excellence ability to enroll clinical trials Partnering Success and M&A Experience Commercial Potential of Products Developed Solid Differentiation Strategy Liquidity - High Probability either through M&A or out-licensing